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Abstract 5-Hydroxytryptamine (5-HT) has been shown to 
exert positive inotropic, chronotropic, and lusitropic effects and 
to stimulate the L-type calcium channel current (7ca) in human 
atrial tissue through activation of the pharmacologically defined 
5-HT4 receptor subtype. However, the molecular nature of the 
receptor(s) involved in these effects is still unknown. In the 
present study, we report the molecular nature of a 5-HT4 
receptor cloned from human atrium, h5-HT4A. Sequence 
analysis reveals that h5-HT4A displays a 93% protein identity 
with the short form of the 5-HT4 receptor recently isolated from 
rat brain. h5-HT4A mRNA is expressed in human atrium but not 
ventricle, and is also found in brain and GI tract. h5-HT4A 
transiently expressed in COS-7 cells displays a classical 5-HT4 
pharmacological profile. However, affinities of the h5-HT4A 
receptor for agonists such as ML10302, BIMU1, renzapride or 
zacopride were 4-10-fold lower than the ones found in brain. 
Moreover, the stimulatory patterns of cAMP formation by h5-
H T 4 A in response to the 5-HT4 agonists ML10302 and 
renzapride were very similar to the patterns of stimulation of 
7ca obtained in response to these compounds in human atrial 
myocytes. We conclude that h5-HT4A likely mediates the effects 
of 5-HT in human atrium and may differ from 5-HT4 receptor 
isoforms present in the brain and GI tract. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Serotonin (5-hydroxytryptamine, 5-HT) exerts strong posi-
tive chronotropic, inotropic and lusitropic effects in human 
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Abbreviations: 5-HT, 5-hydroxytryptamine (serotonin); 5-MeOT, 
5-methoxytryptamine; BIMU1, endo-JV-(8-methyl-8-azabicy-
clo[3.2.1]oct-3-yl)-2,3-dihydro-3-ethyl-2-oxo-lH-benzimidazole-l-
carboxamide; GI, gastrointestinal tract; GR113808, [l-[2-(methylsul-
phonyl)amino]ethyl]-4-piperidinyl]methyl 1-methyl-lH-indole-3-car-
boxylate; /ca, L-type calcium current; ML10302, 2-piperidinoethyl 4-
amino-5-chloro-2-methoxybenzoate hydrochloride; ML10375, 2-(cis-
3,5-dimethylpiperidino)ethyl 4-amino-5-chloro-2-methoxybenzoate; 
PEI, polyethylenimine; renzapride, (± )-endo-4-amino-5-chloro-2-
methoxy-JV-(l-azabicyclo[3.3.1]non-4-yl)benzamide monhydrochloride 
(BRL 24924); zacopride, 4-amino-5-chloro-2-methoxy -7V-(l-azabicy-
clo[2.2.2]oct-3-yl)benzamide monhydrochloride 
and pig atrium [1,2]. These effects are due to (i) 5-HT binding 
to the pharmacologically defined 5-HT4 receptor [3,4], leading 
to (ii) stimulation of adenylyl cyclase activity, (iii) activation 
of cAMP-dependent protein kinase and (iv) phosphorylation 
of several key proteins involved in the excitation-contraction 
coupling. One of these proteins is the L-type Ca2+ channel 
[3,5]. Indeed, in isolated cells from human right atrial append-
age, 5-HT induces a stimulation of the cardiac L-type Ca2+ 
current (Zca) [3] similar to the effect of (3-adrenergic agonists 
such as isoprenaline [5]. However, unlike P-adrenergic ago-
nists, 5-HT exerts its effects exclusively on the atrial tissue 
and has no functional effects on ventricles [1,6]. Moreover, 
while the cardiac effects of (3-adrenergic agonists are univer-
sally present in the animal kingdom, the cardiac effects of 
5-HT are restricted to only few mammalian species (human, 
pig, monkey), and are absent in a large number of laboratory 
animals, such as rat, guinea pig, rabbit and frog [2,3]. In 
human heart, the unique location of 5-HT4 receptors in the 
atrium, together with its stimulatory effect on 7ca> makes it 
reasonable to assume that 5-HT4 receptors may participate in 
the control of cardiac rhythmic and/or arrhythmic activity [7]. 
Endogenous serotonin, which is released from platelets in hu-
man heart, may contribute to the occurrence of atrial fibrilla-
tion and stroke [7]. These possible pathophysiological impli-
cations of human cardiac 5-HT4 receptors make it urgent to 
define the molecular nature of the receptor(s) involved and to 
synthesize appropriate ligands which would bind selectively to 
these receptors. 
However, to our knowledge, the molecular identity of the 
human cardiac 5-HT4 receptor(s) remains unknown. 
Although initial physiological experiments suggested that 
these receptors were similar to the 5-HT4 receptor subtype 
that has been pharmacologically characterized in primary cul-
tures of fetal mouse colliculi neurons, a number of results 
suggest that the human atrial 5-HT4 receptor differs from 
the rodent neuronal 5-HT4 receptor [2,4,8]. The main differ-
ences concern the sensitivities of cardiac and neuronal 5-HT4 
receptors to benzamides, such as renzapride and cisapride. 
While these compounds behave as potent and full agonists 
of the 5-HT4 receptors in mouse colliculi neurons, they are 
less potent and only partial agonists (compared to 5-HT) in 
human heart [4,8]. Other differences exist between the func-
tional response and sensitivities to 5-HT4 receptor agonists 
and antagonists in brain and GI tract [4,8]. Whether these 
differences are due to species differences of the same receptor 
or to different 5-HT4 receptor subtypes mediating the func-
tional response to 5-HT in brain, GI tract and heart remains 
unknown. A 5-HT4 receptor was recently cloned from rat 
brain [9] and two splice variants (r5-HT4L and r5-HT4g) 
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have been identified. These variants differ in the length and 
sequence of their C-termini. The long form (r5-HT4L), which 
has also been cloned recently in mouse colliculi neurons 
(m5-HT4L, [10]), has transcripts present in about every part 
of the brain. However, according to Gerald et al. [9], the short 
form (r5-HT4s) is only present in the striatum while, accord-
ing to Claeysen et al. [10], both splice variants are ubiqui-
tously present in every part of the mouse and rat brain. An 
interesting observation comes from the peripheral distribution 
of r5-HT4L and r5-HT4s transcripts in the rat. While both 
forms are expressed in G I tract (ileum and colon), only the 
r5-HT4s transcript is found in the heart [9]. Moreover, 
r5-HT4s was found to be located exclusively in the atr ium 
[9]. Thus, it is tempting to hypothesize that the cardiac effects 
of 5-HT are mediated by the short splice variant, while the 
long form may determine most of the neuronal effects of 
5-HT. This hypothesis is supported by the identity between 
the pharmacological profiles of the cloned mouse m5-HT4L 
receptor and the native 5-HT4 receptor in mouse colliculi 
neurons [10]. However, a serious drawback in this hypothesis 
is that al though 5-HT4 receptor transcripts are present in rat 
atrium, no cardiac effect of 5-HT related to 5-HT4 receptors 
has been reported to date in this animal species [3]. 
These observations prompted us to characterize the molec-
ular nature of the 5-HT4 receptors expressed in the human 
heart where their functional role has been well documented. 
We report here the molecular nature of a 5-HT4 receptor 
cloned from human atrium. This receptor is the first receptor 
of this kind characterized in human, and we therefore named 
it h5-HT4A. h5-HT4A is expressed in atr ium but not in ven-
tricle. h5-HT4A displays a 93% protein identity with the short 
splice variant of the rat 5-HT4 receptor, r5-HT4s. I15-HT4A 
transiently expressed in COS-7 cells displays a classical 
5-HT4 pharmacological profile. However, affinities of the 
cloned h5-HT4A receptor for agonists such as M L 10302, 
B I M U 1 , renzapride or zacopride were lower than the ones 
found in brain. Moreover, the stimulatory patterns of 
c A M P formation by h5-HT4A in response to the 5-HT4 re-
ceptor agonists M L 10302 and renzapride were very similar to 
the patterns of stimulation of /ca by 5-HT obtained in re-
sponse to these two compounds in isolated human atrial my-
ocytes. Thus, h5-HT4A likely mediates the effects of 5-HT in 
human atrium, and may differ from the 5-HT4 receptor iso-
form(s) responsible for the neuronal effects of 5-HT. 
2. Materials and methods 
2.1. Surgery 
All protocols for obtaining human cardiac tissue were approved by 
the Ethics Committee of our institution (GREBB, Hopital de Bicetre, 
Universite de Paris-Sud). Specimens of right atrial appendages were 
obtained from nine patients (aged 11-74 years) undergoing heart sur-
gery for congenital defects, coronary artery diseases or valve replace-
ment at the Hopital Marie-Lannelongue, Le Plessis-Robinson, 
France. Most patients received a pharmacological pretreatment (Ca-
channel blockers, fi-adrenergic antagonists, ACE-inhibitors, NO-do-
nors, and/or anti-arrhythmic drugs). In addition, all patients received 
sedatives, anesthesia, and, antibiotics. Dissociation of the cells was 
realized immediately after surgery. Human atrial mRNAs used for 
the PCR cloning of the receptor were prepared from the left atrium 
that was harvested postmortem on a patient at the Hopital Marie-
Lannelongue. 
2.2. PCR cloning and rapid amplification of cDNA ends 
The sequence of the recently characterized rat 5-HT4 receptor [9] 
was used to synthesize two pairs of degenerate primers corresponding 
to a region comprised between the third and the seventh transmem-
brane domains of the receptor. Primers HT41 [5'-ATA(C/T)T(A)C 
(G)IC(T/A)TIGAC(T)C(A)GA(T/G/C)TAC(T)-3'] and HT46 [5'-GA-
C(T)CCA(T/G/C)TTC(T)ATA(T/C)GAC(T)TAC(T)AC-3'] were used 
to amplify 50 ng of total RNA from human atrium that was reverse 
transcribed using oligo(dt) primers and Superscript reverse transcrip-
tase (Gibco-BRL). Products of this first PCR reaction were used as 
templates for a second PCR amplification using degenerate primers 
HT42 [5'-AGCTACCGGAATTCATGC(T)TIGGA(T/G/C)GGA(T/ 
G/C)TGC(T)TGG-3'] and HT43 [5'-GCTAGCCCAAGCTTC(T)-
TTC(T)GTA(T/G/C)ACA(T/G/C)AAC(T)ATA(C/T)-3']. Both PCR 
reactions were performed using the following cycle conditions: dena-
turation for 1 min at 94°C, annealing for 1.5 min, and extension for 
2 min at 72°C with the final extension for 8 min. The annealing 
temperatures of cycles 1-2 and 3-30 were 37°C and 54°C, respectively. 
DNA fragments of about 430 bp, which are the expected size of 
5-HT4 receptor-related sequences, were cloned into pGEM7Z 
(EcoRl-Hindlll cut) and sequenced. To obtain the cDNA from 3'-
and 5'-ends, the anchored-RACE extension method was applied as 
described [11], using primers which were specific for the central part of 
the human 5-HT4 cDNA. For the amplification of the 3'-end of the 
gene, the RACE reaction was performed using primer HTS1 
[5'-GAACTCTAACTCTACGTA-3'] together with the first anchor, 
and the nested RACE reaction using primer HTS3 [5'-ATGGTCAA-
CAAGCCCTAC-3'] together with the second anchor. To obtain 
cDNA from the 5'-end of the gene, a reverse transcription using 
specific primer HTS2 [5'-CCCATGATGATGCACAGG-3'] was fol-
lowed by the addition of a polyA tail to the 3' of the cDNA as 
described [11] using the Terminal Deoxynucleotidyl Transferase ac-
cording to the manufacturer instructions (Pharmacia). The RACE 
reaction was then performed using specific primer HTS2 together 
with the first anchor, and the nested RACE reaction using primer 
HTS4 [5'-CCGACTGAGGCCTGCTCTCG-3'] together with the sec-
ond anchor. All reactions used in this RACE-PCR strategy were as 
follows: 30 cycles (1 min at 94°C, 1 min at 55°C and 1.5 min at 72°C) 
and a final elongation (8 min at 72°C). PCR fragments generated by 
this method were cloned and sequenced. After determination of the 
complete cDNA sequence, total cDNA was amplified by PCR using 
specific primers HHT45 [5'-CGGTGCTTATTTCCTGTAATG-3'] 
and HHT43D [5'-TGAATGCGAATGAATGGCTA-3']. 
2.3. Tissue localization studies 
Total RNA were prepared from human peripheral tissues using the 
Trizol RNA purification system (Gibco-BRL). Total RNA from hu-
man brain was from Clontech. cDNA was prepared from mRNA 
using oligo(dT) primers and Superscript reverse transcriptase (Gib-
co-BRL). cDNA specific for the human 5-HT4 receptor was detected 
using a nested PCR amplification. A first reaction was performed 
using 50 ng of cDNA together with specific primers HHT45 and 
HHT43D, designed to the 5'- and 3'-end of the cloned cDNA, re-
spectively. Products of this first reaction were used as templates for a 
nested PCR amplification with specific primers HTS13 [5'-ACATCT-
CTGGACGTCCTGCT-3'] and HHT43C [5'-GTTGTGAGCCATG-
TCCTCA ATCA-3']. The PCR products were run on a 1.5% agarose 
gel and transferred to nitrocellulose membranes. Filters were hybrid-
ized with the 32P-5'-end-labeled internal primer HTS5 [5'-GGCTGC-
TGGGTCATCCCCAC-3'] and washed under high stringency. To 
assess relative quantities of cDNA from different tissue sources, a 
single-PCR amplification was performed using reverse and forward 
primers specific for the rat/human p-actin: [5'-CACCTTCTACAAT-
GAGCTGCGTGTGGC-3'] and [5'-TGTTTGCTGATCCACATCT-
GCTGGAAGGTGGA-3'], respectively. All PCR reactions in tissue 
localization studies were performed as follows: 25 cycles (1 min at 
94°C, 1 min at 55°C and 1.5 min at 72°C) and a final elongation (8 min 
at 72°C). 
2.4. DNA transfection 
The full coding region of the h5-HTiA gene was subcloned in the 
mammalian expression vector pRC/CMV (Invitrogen, Carlsbad, CA). 
Transfections were performed using the vector Polyethylenimine (PEI) 
as described [12]. Cells were transfected using a mixture of DNA and 
PEI at a ratio of 20 nmol PEI/ug DNA in 0.9% NaCl. For radio-
ligand binding assays, COS-7 cells were seeded 1 day before trans-
fection into 1.5 104 mm2 culture vials at a density of 1.5 X 107 cells/ 
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vial, incubated for 6 h with plasmid DNA (150 ug/vial) and harvested 
48 h after transfection. For measurement of cAMP formation, COS-7 
cells were seeded 1 day before transfection into 12-well plates at a 
density of 5X105 cells/well, incubated for 6 h with plasmid DNA 
(16 ug/well) and assayed 24 h after transfection. Cells transfected 
with the h5-HT4A cDNA construct were compared with mock-trans-
fected cells that were exposed to the crude pRC/CMV plasmid. 
2.5. Membrane preparation 
Each vial of cells for use in radioligand binding assays was washed 
twice with phosphate-buffered saline (PBS). Cells were scraped, col-
lected and centrifuged at 300 Xg for 5 min. The pellet was re-sus-
pended in 2.5 ml of ice-cold HEPES buffer (50 mM, pH 7.4), and 
homogenized by an Ultraturax tissue grinder. The lysate was subse-
quently centrifuged at 40000Xg for 20 min at 4°C. The resulting 
pellet was re-suspended in 15 vol. of HEPES buffer (50 mM, pH 
7.4). Membrane preparations were kept on ice and utilized within 
2 h for the radioligand binding assays. 
2.6. Radioligand binding assays 
Radioligand binding studies were performed in 500 ul of buffer 
(HEPES, 50 mM, pH 7.4), 20 ul of either competing agent (for 
drug competition studies), ML10375 to give a final concentration of 
10 |xM (for determination of non-specific binding) or buffer (for de-
termination of total binding), 20 ul of [3H]GR113808 (Amersham, 
Arlington Heights, IL) to give a final concentration of 0.1 nM and 
50 ul (100-200 ug) of membrane preparation. Saturation studies were 
conducted using [3H]GR113808 at nine different concentrations rang-
ing from 0.01 to 3.5 nM. Tubes were incubated at 25°C for 30 min. 
The reaction was terminated by rapid vacuum filtration through 
Whatman GF/B filter paper using the 48R cell Brandel Harvester. 
Filters were pre-soaked in a solution of polyethylenimine (PEI, 
0.1%) to reduce binding to filters. Filters were subsequently washed 
with ice-cold buffer (50 mM Tris-HCl, pH 7.4) and placed overnight 
in 4 ml of Ready-Safe scintillation cocktail (Beckman, Fullerton, CA). 
Radioactivity was measured using a Beckman LS 6500C liquid scin-
tillation counter. Binding data were analyzed by computer-assisted 
non-linear regression analysis (Graph Pad PRISM Program, Graph 
Pad Software Inc., San Diego, CA). 
2.7. Measurement of cAMP formation 
For measurement of intracellular cAMP accumulation, transiently 
transfected COS-7 cells were incubated 24 h after transfection in Dul-
becco's modified Eagle's medium containing 5 mM theophylline, 
10 mM HEPES and 10 uM pargyline for 15 min at 37°C, 5% C0 2 . 
5-HT (1 uM), other serotoninergic agents (1 uM) or forskolin (10 uM) 
were added and incubated for an additional 15 min at 37°C, 5% CO2. 
The reaction was stopped by aspiration of the medium and addition 
of 500 ul of ice-cold ethanol. After 1 h at room temperature, the 
ethanol fraction was collected and lyophilized. The pellet was recon-
stituted and cAMP was quantified using a radioimmunoassay (kit 
79830, ERIA, Diagnostics Pasteur, Marnes La Coquette, France). 
2.8. Human atrial cell dissociation 
Myocytes were isolated as described previously [13,14]. Human at-
rial cell suspension (100-200 ul) was put in a Petri dish containing 
control external solution. 
2.9. Electrophysiological experiments 
The whole-cell configuration of the patch-clamp technique was used 
to record the high-threshold calcium current (Tea) on Ca2+-tolerant 
human atrial myocytes [14]. In the routine protocols the cells were 
depolarized every 8 s from a holding potential of —80 mV to 0 mV for 
200 or 400 ms after a short prepulse (50 ms) to —50 mV. The prepulse 
together with the application of tetrodotoxin (30 uM) was used to 
eliminate fast sodium currents. In some experiments all sodium ions 
were substituted for tetraethylammonium (TEA) ions to prevent so-
dium currents, without any detectable incidence on the results com-
pared to those obtained with sodium-containing solutions. K+ cur-
rents were blocked by replacing all K+ ions with intracellular Cs+ and 
extracellular Cs+ or TEA+ . All experiments were done at room tem-
perature (19-25°C). 
2.10. Solutions 
Control external solution contained (in mM): 107.1 NaCl, 
10 HEPES, 40 CsCl, 4 NaHC03 , 0.8 NaH2P04 , 1.8 CaCl2, 1.8 MgCl2, 
5 D-glucose, 5 sodium pyruvate, 0.03 tetrodotoxin, pH 7.4 adjusted 
with NaOH. TEA external solution contained (in mM): 136.9 TEAC1, 
10 HEPES, 5 D-glucose, 1.8 CaCl2, 1.8 MgCl2, pH 7.4 adjusted with 
TEAOH. Control or drug-containing solutions were applied to 
the exterior of the cell by placing the cell at the opening of 250 um 
inner diameter capillary tubings flowing at a rate of =: 10 ul/min. 
Patch electrodes (0.8-1.5 M£2) were filled with control internal solu-
tion that contained (in mM): 119.8 CsCl, 5 EGTA (acid form), 
4 MgCl2, 5 creatine phosphate disodium salt, 3.1 Na2-ATP, 
0.42 Na2-GTP, 10 HEPES, 62 uM CaCl2 (pCa 8.5), pH 7.3 adjusted 
with CsOH. 
2.11. Data analysis 
The maximal amplitude of Tea was measured as the difference be-
tween the peak inward current and the leak current, which was the 
current amplitude at the end of the 400 ms duration pulse [14]. Cur-
rents were not compensated for capacitive and leak currents. The 
results are expressed as mean ± SEM. The variations in Tea induced 
by 5-HT or ML10302 were tested for statistical significance by Stud-
ent's t test. 
2.72. Materials 
Collagenase type IV and protease type XXIV were purchased from 
Sigma (LTsle d'Abeau Chesnes, France). PEI (MW 800 kDa) was 
from Fluka (LTsle d'Abeau Chesnes, France). DMEM was obtained 
from Gibco-BRL. Tetrodotoxin was from Latoxan (Rosans, France). 
All other drugs were from Sigma. ML10302 and ML10375 were syn-
thetized as recently described [15,16]. All drugs were dissolved in ionic 
aqueous solution. PCR were performed on a GeneAmp 2400 appara-
tus (Perkin Elmer). HiTaq DNA polymerase and related reaction 
buffer was from Bioprobe Systems (Montreuil-sous-Bois, France). In 
all PCR reactions, dNTPs and specific primers were at a final con-
centration of 200 uM and 1 uM, respectively. Doubled-stranded DNA 
was sequenced with a T7 DNA Polymerase sequencing kit (Pharma-
cia) according to the manufacturer instructions. 
3. Results 
3.1. Primary structure of human 5-HT4 receptor 
A 430 bp D N A fragment was isolated when human atrial 
R N A was used as template in a nested RT -PCR amplification 
with two pairs of degenerate oligonucleotide primers derived 
from the central region of the rat 5-HT4 receptor subtype. The 
corresponding full-length c D N A was then isolated from the 
same atrial R N A preparation using an anchored-RACE P C R 
strategy (see Section 2). The deduced amino acid sequence are 
shown in Fig. 1. The nucleotide and peptide sequences were 
90% and 93% identical, respectively, to the short form of the 
rat 5-HT4 receptor, r5-HT4s [9]. The sequences from the two 
species display a common length of 387 amino acids. The 
region of the receptor isolated from human atrium that pre-
cedes the splicing site described in the r5-HT4s receptor also 
shares 94% protein identity with the m5-HT4L receptor re-
cently cloned from mouse colliculi neurons [10]. We have 
therefore isolated the first human 5-HT4 receptor subtype, 
that we propose to name h5-HT4A. The hydrophobicity plot 
displayed seven hydrophobic putative membrane-spanning re-
gions, labelled T M 1 - T M 7 in Fig. 1. Finally, h5-HT 4 A dis-
played all the potential regulatory sites (two N-linked glyco-
sylation sites, a palmitoylation site, three protein kinase C 
consensus sites) already described for r5-HT4s and m5-HT4L 
[9,10]. 
3.2. Tissue-specific expression of the h5-HT\^ receptor 
The expression of h5-HT4A transcripts was analyzed by 
amplification of c D N A derived from R N A isolated from var-
ious human tissues using a nested R T - P C R technique. We 
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h5-HT4 A MDKLDANVSSEEGFGSVEKWLLTFLSgVILMAILGNLLVMVAVCWDRQL 50 
m5-HT4L N R Afl R 
TMl 
r5-HT 4 s NA g M 
h5-HT4 A RKIKTNYFIVSLAFADLLVSVLVMPFGAIELVQDIWSIYGEVFCLVRTSLD 100 
m5-HT4L 3 M 
TM2 
r5-HT 4 s M 
h5-HT4 A VLLTTASIFHLCCISLDRYYAICCQPLVYRNKMTPLRIALMLGGCWVIPT 150 
m5-HT4L L M 
TM3 TM4 
r5 -HT 4 s V V H E 
h5-HT4A FISFLPIMQGWNNIGIIDLIEKRKFNQNSNSTHCVFMVNKPYAITCSWA 200 
m5-HT4L V V SH S 
TM5 
r5-HT4s Q T 0 
h5-HT4A FYIPFLLMVLAYYRIYVTAKEHAHQIQMLQRAGASSESRPQgADQHSTHR 250 
m5-HT4L Q T § 
o o 
r5-HT4S V F EK 
h5-HT4A MRTETKAAKTLCIIMGCFCLCWAPFFVTNIVDPFIDYTVPGQVWTAFLWL 300 
m5-HT4L V F E 
TM6 
r5-HT4s K P 
h5-HT4A GYINSGLNPFLYAFLNKSFRRAFLIILCCDDERYRRPSILGQTVPCSTTT 350 
m5-HT4L K P 
O A 
TM7 
r5-HT4s S Q 
h5-HT4A INGSTHVLRYTVLHRGHHQELEKLPIHNDPESLESCF* 387 
m5-HT4L 
t 
Fig. 1. Comparison of the amino acid sequences of the h5-HT4A receptor cloned from human atrium with the r5-HT4s receptor cloned from 
rat brain, and with the region of the m5-HT4L receptor cloned from mouse colliculi that precedes the splicing site described in the rat 5-HT4 
receptor. The seven putative transmembrane domains are underlined and labelled TMl to TM7. Changes in human amino acids versus rat 
and/or mouse are indicated: differences common to two species are shaded in grey, and absolute differences are shaded in black. • , Potential 
N-linked glycosylation sites; O, protein kinase C consensus phosphorylation sites; A, potential palmitoylation site; T, site of alternative splic-
ing described for the rat 5-HT4 receptor; *, terminal stop codon. The Genebank accession number for h5-HT4A is (pending). 
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Fig. 2. RT-PCR analysis performed with 50 ng of mRNA from var-
ious human tissues. The PCR products were analyzed by Southern 
blotting using a 32P-5'-end-labeled internal primer. The PCR prim-
ers used for this analysis are described in Section 2. An 8 h expo-
sure of the autoradiogram is shown. A positive control was per-
formed using rat actin primers on mRNA samples treated with 
(+RT) or without (—RT) reverse transcriptase. The PCR products 
were analyzed on a 1.5% agarose gel and a photograph of the ethi-
dium bromide stained gel is shown. 
were able to examine the tissue distribution by using two pairs 
of specific primers and two successive rounds of PCR ampli-
fication. The amplified products were identified using a spe-
cific internal oligonucleotide probe (Fig. 2). We also demon-
strated the presence in all tissues of cDNA corresponding to 
the constitutively expressed P-actin gene, as well as the ab-
sence of actin PCR product in a minus reverse transcriptase 
control (Fig. 2). Interestingly, h5-HT4A in the human heart 
was expressed at high levels in the atrium, but not in the 
ventricle. h5-HT4A was also found in whole brain prepara-
tions, and at high levels in the ileum (Fig. 2). These hybrid-
ization signals were not due to any contaminating genomic 
DNA since no bands were observed when RNA was directly 
amplified (—RT control). 
3.3. Pharmacological characterization of the h5-HTiA receptor 
The cDNA encoding the h5-HT4A receptor was transiently 
expressed in COS-7 cells for pharmacological evaluation. Sat-
uration analysis revealed a single saturable site of high affinity 
(Ad = 0.23 ±0.06 nM) using [3H]GR113808 (Fig. 3A). The 
h5-HT4A receptor expressed in COS-7 cells displayed a 5 m a x 
of 0.21 ±0.01 pmol/mg of protein. Non-specific binding in-
creased linearly with increasing ligand concentration. A range 
of 5-HT4 receptor agonists and antagonists completely inhib-
ited the specific binding of [3H]GR113808 to the cloned 
h5-HT4A receptor (Fig. 3B). All the displacement curves 
were monophasic, giving a Hill coefficient not different from 
1. The degree of non-specific binding at 0.1 nM of 
[3H]GR113808 ranged from 5 to 11% depending on experi-
ments. The data summarized in Table 1 demonstrate that the 
pharmacological profile of the cloned h5-HT4A receptor, in 
terms of rank order of potencies of the ligands tested, is 
very similar to the one found for 5-HT4 receptors as studied 
in situ (human [17] and piglet [18] atria, human striatum [19] 
and caudate [20], rat [15,16] and guinea pig [21] striatum, 
mouse colliculi [21]) or after expression of cloned isoforms 
in cultured fibroblasts (r5-HT4L [9,22] and m5-HT4L [10]). 
However, the h5-HT4A receptor displayed lower affinities for 
all the agonists and partial agonists tested when compared to 
human brain preparations, or cultured fibroblasts expressing 
the r5-HT4L and m5-HT4L receptors. When affinity estimates 
for 5-HT4 agonists in piglet or human heart tissue were avail-
able in the literature, these values were much closer to the one 
found in COS-7 cells expressing the h5-HT4A receptor than 
affinity values found in neuronal tissues or in cells expressing 
the long form of the 5-HT4 receptor (r5-HT4L or ITI5-HT4L). 
Binding data concerning the short form of the 5-HT4 receptor 
cloned in rat are not available in the literature. 
3.4. Stimulation of cAMP production by the hS-HT/^ receptor 
To examine the ability of cells expressing h5-HT4A to cou-
ple to adenylyl cyclase, cAMP synthesis was assayed in COS-7 
cells transiently transfected with the h5-HT4A cDNA. Basal 
cAMP values were not significantly different in cells express-
ing the h5-HT4A receptor and in mock-transfected cells 
(9.94± 1.61 and 7.60± 1.54 pmol/well, respectively), indicating 
that the h5-HT4A receptor had no intrinsic activity on cAMP 
formation in transiently transfected cells in the absence of 
agonists. cAMP responses to various 5-HT4 receptor agonists 
and to forskolin are represented in Fig. 4 as % increase over 
basal cAMP concentration. 5-HT (1 u\M) had no effect on 
basal adenylyl cyclase activity in mock-transfected COS-7 
cells, indicating that endogenous adenylyl cyclase-coupled se-
rotonin receptors are not present in these cells. In I15-HT4A 
clones, addition of 5-HT (1 uM) increased cAMP concentra-
tion by 99%. The 5-HT4 agonist ML10302 (1 uM: [16]) be-
haved as a poor 5-HT4 agonist in h5-HT4A clones, and in-
creased cAMP concentration by only 28%, despite an affinity 
for the receptor that was found = 9 0 times higher than the 
one of 5-HT (Table 1). Furthermore, pre-incubation of 
h5-HT4A clones with 1 nM ML10302 prior to addition of 
5-HT antagonized significantly the ability of 5-HT (1 |iM) 
to increase basal cAMP levels (Fig. 4). Renzapride also be-
haved as a poor 5-HT4 agonist, and increased cAMP forma-
tion by only 53%, despite an affinity for the h5-HT4A receptor 
similar to the one of 5-HT (Table 1). Forskolin (10 |0.M), a 
direct activator of adenylyl cyclase, induced a similar increase 
in cAMP concentration in h5-HT4A clones and in mock-trans-
fected COS-7 cells, indicating that the potential for maximal 
activation of adenylyl cyclase was not impaired in cells ex-
pressing the h5-HT4A receptor. 
3.5. 5-HT regulation of calcium current in human atrial 
myocytes 
To examine whether h5-HT4A may mediate the cardiac ef-
fects of 5-HT in human atrium, we have re-examined the 
5-HT4 receptor mediated regulation of Tea in isolated human 
atrial myocytes. Since the most striking results obtained with 
the cAMP response mediated by the cloned h5-HT4A con-
cerned the agonist/antagonist properties of ML 10302, we 
compared the effects of ML 10302 and 5-HT on /ca- Basal 
/ca amplitude, measured at 0 mV membrane potential, was 
on average 192.3 ±33.9 pA (« = 21), and Tea density, which 
represents the ratio of Tea amplitude to membrane capaci-
tance, was 3.0 ± 0.45 pA/pF (w = 21). Like on the cAMP meas-
urements, the effects of ML10302 and 5-HT were first tested 
at a 1 \xM concentration. As shown in Fig. 5A, application of 
1 |j,M ML 10302 produced a small and reversible stimulation 
of basal /ca amplitude. The individual current traces shown in 
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Fig. 3. A: Saturation analysis of [3H]GR113808 binding on h5-HT4A clones. Membranes harvested from transiently transfected COS-7 cells 
were incubated with 8 concentrations of [3H]GR113808 (0.02-3.3 nM) for 30 min at 25°C. Non-specific binding was defined by 10 uM 
ML10375. Results are from a single experiment but are representative of three such experiments. KD and Smax values were determined by com-
puter-assisted non-linear regression analysis (GraphPad, Prism Software). B: Inhibition of specific [3H]GR113808 binding to the cloned 
h5-HT4A receptor. Membranes from transiently transfected COS-7 cells were incubated with 0.4 nM [
3H]GR113808. Non-specific binding was 
defined by 10 uM ML10375. Results are presented as a percentage of specific binding in the absence of a competing agent. Results are from a 
single experiment but are representative of three such experiments. Data were analyzed by computer-assisted non-linear regression analysis 
(GraphPad, Prism Software). 
the top panel of Fig. 5A demonstrate that the effect of 
ML 10302 was not accompanied by any significant modifica-
tion in the kinetics of 7ca- This suggests that ML10302 did not 
modify the voltage dependence of the Ca channel gating. 
While ML 10302 had little effect on basal /ca amplitude, ap-
plication of 5-HT after washout of ML 10302 resulted in a 
large stimulation of Tea- In 14 experiments in which both 
ML 10302 and 5-HT were successively tested on the same cells 
(like in Fig. 5A), 1 uM ML 10302 and 1 uM 5-HT increased 
7Ca by, respectively, 17.4 ± 8.0% and 157.0 ± 40.6% over a con-
trol amplitude of 117.5 ±24.5 pA. Thus, similarly to the 
cAMP response mediated by the cloned h5-HT4A, ML 10302 
behaved as a poor activator compared to 5-HT of the L-type 
calcium current in human atrial myocytes. 
To examine whether ML 10302 behaved as an antagonist of 
the native human cardiac 5-HT4 receptors, the effect of 
ML10302 on Tea was tested in a different series of experiments 
by adding the compound in the presence of 5-HT. Fig. 5B 
shows that application of 1 |jM ML 10302 in the presence of 
1 u,M 5-HT resulted in a reduction of the stimulatory effect of 
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5-HT on /ca- In four similar experiments in which 5-HT 
(1 uM) was applied first and ML10302 (1 uM) was added 
later on top of 5-HT, 5-HT alone increased Zca by 121.3 ± 
42.4% over basal level, and ML10302 reduced this effect to 
60.0 ± 16.0%. To further characterize the inhibitory effect of 
ML10302 on 7ca> a cumulative concentration-response curve 
was obtained by adding increasing concentrations of M L 10302 
(1-100 nM) to cells initially exposed to 100 n M 5-HT. As 
shown in Fig. 5C, 100 n M 5-HT alone increased 7ca by 
195.9 ±26 .0% ( « = 1 3 ) over its basal amplitude. Increasing 
concentrations of M L 10302 progressively reduced this effect 
to 71.8 ± 1 2 . 8 % (« = 6) at the maximal concentration tested 
(100 nM) . Thus, ML10302 antagonized the response of Tea 
to 5-HT in a concentration-dependent manner. At a 100 n M 
5-HT concentration, the IC50 for M L 10302 was 17 n M and 
the maximal effect was « 7 0 % inhibition of the 5-HT 
response (Fig. 5C). Thus, similarly to the c A M P response 
mediated by the cloned h5-HT4A, M L 10302 behaved as an 
antagonist of the 5-HT mediated response in human atrial 
myocytes. 
4. Discussion 
In the present study, we have used degenerate oligonucleo-
tide primers designed from the sequence of the rat 5-HT4 
c D N A and a PCR-based strategy to isolate and clone 
5-HT4 receptor-related sequences from human atrium. We 
have identified the sequence of a protein cDNA, that we 
have named h5-HT 4 A . We believe that h-5HT4A is the first 
reported sequence of a human 5-HT4 receptor c D N A since 
Table 1 
Comparison of the binding affinities of various 5-HT4 receptor agonists and antagonists on cloned and native 5-HT4 receptors 
Compounds Ki (nM) 
h5-HT4A in Human Piglet Human Rodent striatum Mouse colli- r5-HT4L in m5-HT4L in 
COS-7 atrium[17] atrium[18] brain[19,20] [15,16,21] culi[21] COS-7[9] LLCPK1[10] 
Agonists 
ML10302 
5-HT 
5-MeOT 
Partial agonists 
BIMU1 
Renzapride 
Zacopride 
Antagonists 
GR113808 
ML10375 
8.4 
772 
2080 
373 
635 
7750 
0.33 
0.56 
1585 
398 
-
251 
6309 
_ 
-
-
_ 
-
-
30.2 a 
501b 
12.3a 
251b 
692a 
0.06a 
-
1.07c 
187c 
2580c 
15.8d 
127° 
1510c 
0.15C 
0.26c 
-
79 
524 
53 
97 
223 
0.32 
-
-
145 
401 
_ 
243 
808 
_ 
-
-
56 
229 
28 
131 
190 
0.2C 
-
The first column indicates the affinities of various compounds that compete for 0.4 nM [3H]GR113808 binding to membranes of COS-7 cells 
transiently transfected with the human h5-HT4A gene. Affinity estimates are given as K[ values in nM and were determined from IC50 values 
obtained by computer-assisted non-linear curve analysis. K\ values are representative of at least two determinations. These results are compared 
with data from the literature (see references in columns 2-8). [3H]GR113808 was used as radioligand in binding studies on the native 5-HT4 
receptor in human striatum, rat striatum, mouse colliculi neurons, and on the cloned r5-HT4L (rat) and m5-HT4L (mouse) receptors expressed in 
fibroblasts. [125I]SB207710 was used as radioligand in binding studies on the native 5-HT4 receptor in human and piglet atria. Binding assays on 
human brain were performed on striatum (a, ref. [19]) and caudate (b, ref. [20]). Binding assays in rodent stratum were from rat (c, ref. [15,16]) and 
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our results demonstrate that: (i) the deduced amino acid se-
quence of 1I5-HT4A displays a 93% identity with the short 
form of the 5-HT4 receptor isolated from rat brain (r5-
HT4s, [9]), and a 94% identity with the region preceding the 
splicing site in the m5-HT4L receptor recently cloned from 
mouse colliculi neurons [10]; (ii) transient expression of 
h5-HT4A in COS-7 cells displays a classical 5-HT4 pharmaco-
logical profile in terms of rank order of potency of the various 
serotoninergic ligands tested [8]; (iii) the cloned h5-HT4A re-
ceptor is positively coupled to adenylyl cyclase. For the rea-
sons detailed below, we believe that h5-HT4A is the 5-HT4 
receptor that mediates the functional response of human at-
rium to 5-HT. 
(1) h5-HT4A mRNA is expressed in human atrium but not 
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in ventricle. This is in agreement with a number of functional 
studies showing positive inotropic and chronotropic effects of 
5-HT which are located exclusively in the human atrial tissue 
[1,6]. This is also in agreement with an expression pattern of 
the 5-HT4 receptor restricted to the atrium in rat heart [9]. 
(2) Transient expression of h5-HT4A in COS-7 cells revealed 
significantly lower binding affinities for all the agonists and 
partial agonists used as compared to the affinity constants 
found in the literature concerning the endogenous 5-HT4 re-
ceptors in neuronal tissues, or in cultured fibroblasts express-
ing the long form of either the rat or the mouse 5-HT4 re-
ceptor (Table 1). However, there was a good correlation 
between the affinity constants of 5-HT, 5-MeOT and renza-
pride for the cloned h5-HT4A receptor and those obtained for 
the same agonists when binding to the native cardiac 5-HT4 
receptors in human and pig atria (Table 1). This suggests that 
I15-HT4A is the receptor accounting for the 5-HT binding sites 
found in human atrium. The differences in binding affinities 
for 5-HT4 agonists observed between heart and brain may be 
due to the presence of different 5-HT4 receptor isoforms in 
these tissues. 
(3) We have examined the ability of h5-HT4A receptors to 
couple to adenylyl cyclase in COS-7 transfected cells. We 
found that 1 uM 5-HT produced a ~ 2-fold stimulation of 
cAMP production. This was much less than what was found 
for the cloned rat and mouse 5-HT4 receptors. Indeed, over-
expression of the rat r5-HT4L receptors in COS-7 cells pro-
duced a ~ 20-fold stimulation of basal cAMP release in re-
sponse to 1 (J,M 5-HT, similar to the stimulation induced by 
10 |xM forskolin [9]. The most likely reason for this discrep-
ancy is a difference in the level of protein expression. The level 
of expression of the h5-HT4A receptor in our system appeared 
to be within the physiological range, since the I15-HT4A recep-
tor density in transiently transfected COS-7 cells was similar 
to the density of endogenous 5-HT4 receptors reported in 
human brain [20]. However, expression of the cloned rat 
5-HT4 receptors also in COS-7 cells led to a receptor density 
of 2.5 pmol/mg protein [9], i.e. > 10-fold higher than the 
density found in our system or in human substantia nigra 
reticulata [20]. Over-expression of the mouse m5-HT4L recep-
tor in LLCPK1 cells led to an even higher receptor density 
( ~ 8 pmol/mg protein) which resulted in a substantial increase 
in basal adenylyl cyclase activity observed even in the absence 
of 5-HT4 agonists [10]. 
(4) Renzapride produced only a moderate stimulation of 
cAMP synthesis in COS-7 cells expressing h5-HT4A- When 
both renzapride and 5-HT were used at a saturating concen-
tration of 1 u,M, renzapride produce only ~ 50% of the effect 
of 5-HT (Fig. 4). This suggests that renzapride behaves as a 
partial agonist (compared to 5-HT) of h5-HT4A receptors. 
However, this partial agonistic activity of renzapride is a gen-
eral feature of native cardiac 5-HT4 receptors [4,8]. For exam-
ple, in isolated human atrial myocytes, the maximal stimula-
tory effect of renzapride on IQ& was only x 40% of that of 
5-HT [3]. By contrast, renzapride behaves as 'superagonist' in 
mouse colliculi neurons, with an intrinsic activity greater than 
5-HT [4]. Thus, the cloned h5-HT4A receptors and the native 
human atrial 5-HT4 receptors shares a clear similitude with 
respect to their sensitivities to renzapride. 
(5) A striking finding in our study was the poor agonistic 
effect, combined with a net antagonism to 5-HT, of ML 10302 
on the cAMP response generated by the cloned I15-HT4A re-
ceptor. ML10302 was shown recently to bind to 5-HT4 recep-
tors in the rat striatum with a nanomolar affinity [15,16]. 
Moreover, ML 10302 mimics the effect of 5-HT, with an 
EC50 of ~4-6 nM, on the relaxation of rat esophagus as 
well as on the electrically evoked contraction of the guinea 
pig ileum [15]. While ML10302 binds to the h5-HT4A receptor 
with a nanomolar affinity (Table 1), it increased cAMP by 
only 30% at a 1 |0.M concentration. Moreover, pre-incubation 
of transfected cells with ML 10302 significantly reduced the 
5-HT stimulation of adenylyl cyclase activity. Again, these 
features appeared representative of the native human atrial 
5-HT4 receptors, since ML 10302, unlike 5-HT, has no stim-
ulatory effect on Tea in human atrial myocytes and exerted a 
dose-dependent inhibition of the stimulatory effect of 5-HT on 
Ic& (Fig- 5). Although the effects of ML10302 were only ex-
amined in rodent CNS and GI tract, it is likely that ML 10302 
also acts as an agonist in human preparations. Thus, the 
absence of stimulatory effect of ML10302 in human atrium 
would suggest that h5-HT4A does not play a major role in the 
response of the CNS and GI tract 5-HT, although this recep-
tor is expressed in these tissues (Fig. 2). Further studies are 
needed to examine whether other member(s) of the 5-HT4 
receptor family participate(s) in the effect of 5-HT in these 
tissues. 
Taken altogether, our data strongly suggest that (i) the 
h5-HT4A receptor is similar to the native 5-HT4 receptor 
which mediates the positive inotropic, chronotropic and lusi-
tropic effects of 5-HT in human atrium, and (ii) differs from 
5-HT4 receptors previously characterized in neurons and the 
GI tract. The simplest hypothesis to explain this tissue-specif-
icity of 5-HT4 receptors is the existence of alternative-spliced 
variants differentially expressed in the CNS and peripheral 
tissues. Modification of the C-termini of receptors by alterna-
tive splicing could induce changes in the potency of various 
agonists and/or antagonists to bind to the receptor. Modifica-
tions of the C-terminal tails of seven-transmembrane-domain 
receptors following alternative splicing has also been shown to 
determine G-protein specificity and hence to affect signal 
transduction pathways [23]. Search for alternative splice-var-
iants of the h5-HT4A receptor and comparative functional 
studies will be needed in the future to test these hypotheses. 
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